

Diabetes Screening for People with Schizophrenia or Bipolar **Disorder Who Are Using Antipsychotic Medications**

CBH is committed to ensuring members receive quality care. This measure assesses annual diabetes screening for members 18 to 64 years of age who are dispensed an antipsychotic medication for schizophrenia or bipolar disorder. People with serious mental illnesses are at an increased risk for diabetes. Antipsychotic medications may also increase risk for developing diabetes, making it important to screen and monitor members who take them.

For more information, see the National Committee for Quality Assurance (NCQA) Behavioral Health Resource Center.

Best Practices

- Screen members for diabetes at least annually, particularly those who do not have regular contact with a primary care physician (PCP).
- The following diabetes screening tests are indicated:
 - » HbA1c
 - Fasting blood glucose
 - Random blood glucose
- Inform members when labs are due and help members find a lab location close to their home.
- Discuss results with members and refer to primary care physician as appropriate for follow up.
- Perform other recommended monitoring, such as: blood pressure, weight, and regularly update medical history and medication lists.
- Collaborate with case management and primary care physicians on member care strategies. Ensure the results are communicated in a timely fashion to other health care providers involved in the care of the member.

Lab Screenings Associated with this Measure

HbA1c Test

CPT: 83036, 83037

Glucose Test

CPT: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951

Resources

- **CBH: HEDIS Tip Sheets**
- **CBH: Pharmacy Resources for Members**
- **CBH: Pharmacy Resources for Providers**
- **CBH: Integrated Care Plan Resources for Members**

Diagnoses Associated with This Measure

- [F20] Schizophrenia
- [F25] Schizoaffective Disorders
- [F30] Manic Episode
- [F31] Bipolar Disorder
- [F32] Major Depressive Disorder, single episode
- [F33] Major Depressive Disorder, recurrent
- [F34] Persistent Mood [affective] Disorder
- [F39] Unspecified Mood [affective] Disorder
- [F29] Unspecified psychosis not due to a substance or known physiological condition
- [F60.3] Borderline Personality Disorder

HealthChoices Preferred Drug List

For reference, see the PA Statewide Preferred Drug List (PDL).

First-Generation Antipsychotics:

Fluphenazine, Haloperidol, Loxapine, Perphenazine, Trifluoperazine

Second-Generation Antipsychotics:

Aripiprazole, Clozapine, Lurasidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone

- **CMS: Measures Inventory Tool**
- **CDC: A1C Test for Diabetes and Prediabetes**
- NCQA Supports Medicaid Behavioral Measure Reporting
- **AHA/ASA Journals: Harmonizing the Metabolic** Syndrome



Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications

Screening for Metabolic Syndrome Components Based on <u>APA Clinical Practice</u> Guideline for the Treatment of Patients with Schizophrenia

Parameter	Suggested Frequency
Metabolic syndrome (currently defined as presence of at least 3 of the following 5 risk factors: elevated waist circumference; elevated triglycerides; reduced HDL-C; elevated blood pressure; and elevated fasting glucose)	Determine if metabolic syndrome criteria are met at 4 months after initiating a new antipsychotic and at least annually thereafter
Vital signs (pulse, blood pressure, temperature)	As clinically indicated
Body weight, height, and Body Mass Index (BMI)	BMI every visit for 6 months and at least quarterly after
Diabetes (screening for diabetes risk factors, fasting blood glucose)	Fasting blood glucose or hemoglobin A1C at 4 months after initiating a new treatment and at least annually after
Hyperlipidemia (lipid panel)	Lipid panel at 4 months after initiating a new antipsychotic medication and at least annually thereafter

Lab Coverage Information

Health Plan	Laboratory Provider
Community Behavioral Health	Atlantic Diagnostic Laboratories Parkway Clinical Laboratories
Jefferson Health Plans	Quest Diagnostics
Keystone First	<u>LabCorp</u>
<u>United Healthcare</u>	LabCorp Quest Diagnostics
Gelsinger	<u>LabCorp</u> <u>Quest Diagnostics</u> <u>Jefferson Health</u>
PA Health and Wellness	LabCorp Quest Diagnostics
<u>UPMC</u>	Quest Diagnostics

Disclaimer: The information contained in this tip sheet is for educational and informational purposes only. The clinical services described in this tip sheet may not be covered for all CBH enrollees. To find out about what services are available to you under the CBH benefit package, please contact CBH Provider Operations at 215-413-3100.